Rivaroxaban prophylaxis too risky for medical inpatientsBMJ 2013; 346 doi: https://doi.org/10.1136/bmj.f875 (Published 13 February 2013) Cite this as: BMJ 2013;346:f875
Medical inpatients who need thromboprophylaxis usually stop treatment when they go home, but the manufacturers of the oral anticoagulant rivaroxaban have been investigating the risks and benefits of extending treatment from the usual 10 days to 35 days. The overall balance did not look favourable …
Log in using your username and password
Log in through your institution
Register for a free trial to thebmj.com to receive unlimited access to all content on thebmj.com for 14 days.
Sign up for a free trial